Cipla launches Niveoli™, India's first extrafine ICS-LABA combination HFA inhaler


Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announces that it has launched Niveoli™, India's first extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targeting drug delivery to the small airways. Niveoli™ is a proprietary Cipla inhaler, and the latest offering from Cipla in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD).

Asthma and COPD are lung conditions that affect the ability to breathe. Extensive research and an evolved understanding of the diseases over the years has shown the significant role of small airway disease in asthma and COPD. A recent meta-analysis showed that small airway disease is prevalent in 50-60% of asthma patients1. Another study has indicated that routine lung function tests can underestimate problems in the small airways2. Small airway disease is a common feature of COPD and gets worse with increasing severity of the condition3. Niveoli™'s novelty and strength lies in HFA propelled delivery of extra-fine particles of beclomethasone, an inhaled corticosteroid (ICS) and formoterol, a fast-onset long acting beta agonist (LABA) to the small airways.

Commenting on the launch, Nikhil Chopra, Head - India business, Cipla, said,
"Cipla is pleased to offer yet another milestone in respiratory inhalation therapy. Niveoli™ marks a first in acknowledging and addressing the issue of drug delivery to the small airways. Cipla has a long history of blazing the trail in innovations in combination formulations and drug-device combinations in the respiratory therapy, and Niveoli™ is a painstaking result of these strengths. Be it the transparent dry powder inhaler, the static-free spacer with valve mechanism, the mask-spacer combination for children or our novel breath-actuated inhaler with dose counter called Synchrobreathe™, the list is long. We see our market leadership as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients. In keeping with our purpose of 'Caring for Life', we are constantly studying OADs and working towards products that offer greater efficacy, ease of use and drug delivery to patients. I believe Niveoli™ represents a new paradigm in inhalation therapy."

Shares of CIPLA LTD. was last trading in BSE at Rs.544.35 as compared to the previous close of Rs. 546.15. The total number of shares traded during the day was 125596 in over 2113 trades.

The stock hit an intraday high of Rs. 554.4 and intraday low of 542.25. The net turnover during the day was Rs. 68868583.

1 Respir Med 2016; 116: 19-27
2 Respir Med 2013; 107: 1667-1674
3 Am J Respir Crit Care Med 2016; 194: 178-184

Comments

Post a Comment

Popular posts from this blog

A morning walk down Dalal Street

Image
technically, the Nifty50 made a fresh record closing high but it reversed gains around 11,958 on that was similar to intraday high of 11,957 on May 27. The rupee May 28 declined by 18 paise to close at 69.69 against the US currency, weighed down by month-end dollar demand from importers and rising crude oil prices. On the institutional front, FPIs were net sellers in Indian markets for Rs 501 crore while DIIs were net buyers to the tune of Rs 269 crore, provisional data showed. Big News: On the earnings front, as many as 617 stocks will declare their results for the quarter ended March which include names like Aban Offshore, Adani Power, Bharat Electronics, Cadila Healthcare, Finolex Cables, GMR Infrastructure, Havells India, IDFC Ltd, IPCA Laboratories, Max India, NBCC etc. among others.   https://www.capitalaim.com/trading/stock-tips  
Read more

Nifty likely to show upmove towards 12,300-12,500 in the coming weeks

Image
Macro data will be in focus… GDP as well as Infrastructure output data for April is scheduled to come out post market hours later today Most experts feel that there is a high likelihood that the GDP growth could have slipped below 7 percent. A Reuters survey of economists forecast growth slipped to 6.3 percent annually in the three months ending in March, its slowest pace in six quarters. The central bank’s monetary policy committee (MPC), which has cut policy rates by 50 basis points this year, is expected to cut the repo rate by a further 25 basis points at its June 4-6 meeting, bringing it to 5.75%, the lowest since July 2010, added the Reuters report. https://www.capitalaim.com/trading/stock-tips
Read more

Nifty stocks trade at a discount to respective 10-year average P/Es

Image
Nifty50 rallied to a fresh record high of 11,856 in April but since then the momentum has fizzled out. The index is down about 3 percent from las month's high and it has also breached its crucial short-term moving averages at 5-days exponential moving average (EMA), 13, 20 and 50-days EMA in May. A large part of the fall can be attributed to selling seen in the largecap stocks and about 25 such companies, or 50 percent, of the Nifty50 constituents are trading below their respective 10-year PE averages. PE multiple, or price-to-earnings ratio, is a valuation metric which measures the current stock price relative to the company's earnings. It is also sometimes referred to as earnings multiple. As many as 25 companies in the Nifty50 basket are trading below their respective 10-year average earnings multiple. These include Eicher Motors, Hero MotoCorp, L&T, Axis Bank, Yes Bank, SBI, NTPC and Power Grid, according to a report by Motilal Oswal. https://www.capitalaim.co...
Read more